A Snapshot of the NGS Market User Views
Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing (NGS). The survey was designed to investigate current trends in NGS usage and determine future demands; to aid OGT in continuing to deliver high-quality, up-to-date services and provide insightful, relevant customer resources. The company received 596 responses from its worldwide database of contacts and donated to the UK charity DEBRA (for the genetic skin blistering condition Epidermolysis Bullosa) for each completed survey.
Responses on the most popular research areas for NGS and choice of methods uncovered a trend towards cost-effective, high-resolution targeted resequencing techniques over whole genome sequencing, with the Illumina platform identified as the leading technology. Cancer and rare disease are the most popular research areas for using NGS, supporting the use of targeted approaches which enable more accurate detection of rare variants.
Challenges in bioinformatics were found to be one of the biggest barriers to NGS implementation, which may explain why over a third of investigators choose to outsource data analysis. Supporting this finding, data quality and bioinformatics expertise are cited in the top three essential factors when choosing an NGS service provider.
Further insights into the use of NGS for clinical tests, preferred NGS methods, and demands on service providers are also presented. Download the full results here.
The survey adds to a growing portfolio of informative resources from OGT on NGS, including a recent whitepaper on choosing the right NGS method and a free-to-download demo version of their innovative and easy to use Genefficiency NGS reporting software.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance